Pharmacological properties: Alfarekin similar natural leukocyte interferon, has three main types of biological activity: immunomodulating, antiviral and anticancer.
The mechanism of action Alfarekina based on the binding of IFN to specific receptors of cells of the body, resulting in triggered cascade of intracellular reactions, and synthesis of enzymes which depress viral replication, increased phagocytic activity of macrophages and lymphocytes specific cytotoxicity on target cells, inhibiting proliferation of metastatic cells.
INDICATIONS: in the complex therapy of children and adults with:
Viral hepatitis B and C;
acute viral, bacterial and mixed infections (including neonatal);
acute and chronic purulent diseases of viral and bacterial origin;
herpetic infections of different localization: (tinea, multiple cutaneous herpetic eruptions, genital herpes infection, herpetic keratoconjunctivitis and keratouveit, etc.);
chronic urogenital chlamydiosis;
lesions of the nervous system with mono-and poliradikulyarnym pain syndrome;
laryngeal papillomatosis;
multiple sclerosis;
malignancies: melanoma of skin and eye cancer, kidney, bladder, ovaries, breast cancer, Kaposi's sarcoma, myeloma;
hemoblastosis: chronic myeloid leukemia, volosatokletochnoy leukemia, non-Hodgkin's lymphoma.
APPLICATION: rr Alfarekina injected i / m, n / k / v, endolimfalno, intraperitoneal, intravesical, rectal, parabulbarno, intranasal. The dissolution of the contents of the vial in 1 ml of water as a solvent used for injection by dissolving the contents of the vial at a higher level using physiological pp.
Acute hepatitis B:
introduced on 1 million IU (in severe cases - by 2 million IU) in / m 2 twice daily for 10 days. The course of treatment may be extended to 2-3 weeks, depending on the patient's general condition, or extended by 1 million IU 2 times a week for several weeks.
Chronic viral hepatitis B:
injected i / m for 3-4 million IU 3 times a week for 2 months.
Chronic viral hepatitis C:
introduced into / m 3 million IU 3 times a week for 6 months as monotherapy or in combination with drugs-nucleoside analogues.
SARS in children (including newborns):
injected intranasally with 2-3 drops into each nasal passage 3-6 times a day for 3-5 days; dosage for newborns - 20-50 thousand IU / ml, for children of other age groups - 100 thousand IU / ml.
Acceptable introduction to the nasal passages (alternately) padded turundae wetted Alfarekinom, 10-15 min.
ARI (including influenza) in adults:
injected i / m by 1-3 million IU, beginning with 1-2 days of disease within 3 days;
intranasal imposed on 4-6 drops of p-ra Alfarekina (100 thousand IU / ml) in each nasal passage 6-8 times a day (to be entered using a dose Alfarekina should be heated in the syringe (use a syringe without the needle) to body temperature, the rest rr stored in the refrigerator, protected from bacterial contamination).
Acute and recurrent viral pneumonia and viral-bacterial etiology:
V / m at 1 million IU for 5-7 days in the complex treatment, including antibacterial, detoxication, anti-inflammatory therapy.
Acute diarrheal syndrome in infants:
rectally in the form of daily mikroklizmochek containing 100 thousand IU Alfarekina within 3-7 days.
Acute intestinal infections in young children with symptoms hypocoagulation:
injected rectally in a dose of 10 thousand IU / kg body weight 3 times with an interval of 48 h.
Purulent-septic disease, peritonitis, multiple abscesses of the abdominal cavity:
in / on 2-4 million IU 1 time per day, total dose: 12-16 million IU per course of treatment.
HSV infection:
zoster: daily / m - 1 million IU, and 2 million IU in 5 ml of physiological p-ra n / a at several points around the zone of the rash. Duration of treatment - 5-7 days.
cutaneous herpetic eruptions: 2 million IU / m or s / c (around lesion) daily; treatment can be combined with local application (applications) on herpetic papules.
Genital herpes infection: 2 million IU / m daily in combination with local application of the drug in the form of applications to the region of eruption.
herpetic keratoconjunctivitis: 1 million IU Alfarekina dissolved in 5 ml of physiological p-ra, injected conjunctiva with 2-3 drops every 2 h for 7-10 days, with decreasing severity of symptoms of a drug can enter every 4 hours
Chronic urogenital chlamydia:
Alfarekin used in complex therapy - to 1 million IU / m 1 times a day in the evening, on a course of treatment - 10 injections.
The defeat of the nervous system with mono-and poliradikulyarnym pain syndrome:
of 1 million IU / m for 5-10 days in the complex therapy.
Laryngeal papillomatosis:
in / m (if possible - in the perifocal area of the larynx) introduction Alfarekina a dose of 100-150 thousand IU / kg of body weight daily for 20-25 days. It is recommended to repeat this course of treatment with an interval of 1-1,5 months within 6 months, followed at intervals of 2-3 months for the next 6 months.
Multiple sclerosis:
V / m at 1 million IU 2-3 times a day for 10-15 days, then - by 1 million IU 1 times per week for 6 months.
Malignancies
Melanoma of the skin - by 3 million IU / m 1 times a day - 10 days with an interval of 1.5 months of repeating this course for 6 months;
or: by 3 million IU Alfarekina 4 times with an interval of 48 hours - endolimfalno followed lymphotropic drug administration for 1 million IU for 4 days every month.
Uveal melanoma: the 1 million IU parabulbarno daily for 10 days, 20 days later to repeat the course within 10 days, 2 times; dose of the drug on the general course of treatment is 30 million IU. Can not exclude the need for repeated courses in 45 days; treatment Alfarekinom combined with photodestruction of the tumor and beta applications.
Kidney cancer: by 3 million IU / m, daily for 10 days, the overall rate - 30 million IU, refresher courses held at intervals of 3-5 weeks for 6 months, and then at intervals of 1,5-2 months in within 1 year.
Bladder cancer: intravesical instillation in the form of, for 5-10 million IU per instillation, 3-6 times. The total course dose - 30 million IUs. The treatment is repeated every 2-3 months for 1 year-2 years.
Cancer of the ovary: 5 million IU injected intraperitoneally during surgery and in the next 5 days - in the drainage, then - at 3 million IU / m for 10 days between courses of chemotherapy, the total course dose Alfarekina of 90 million IU. Subsequent courses may be assigned at intervals of 2-3 months for 1-1,5 years: by 3 million IU / m every day - 10 days.
Breast Cancer: by 3 million IU per injection in / m, daily for 10 days. Repeated courses are held at intervals 1,5-2 months to 1 year and then every 2-3 months (depending on the clinical condition of the patient), appropriate alternate therapy Alfarekinom with courses of chemotherapy (or radiotherapy).
Kaposi's sarcoma: by 3 million IU per injection in / m, daily for 10 days; treatment combined with monohimioterapiey prospidin; repeated courses - 1 time per month for 6 months.
Multiple myeloma: by 3 million IU per injection in / m, daily for 10 days, a second course - 1 times 1,5-3 months (4-6 courses during the year).
Hemoblastosis
Chronic myeloid leukemia: 5 million IU / m daily.
Apply as in the form of mono-and chemotherapy in the complex. Duration of treatment - 6 months. When the phase of remission maintenance therapy Alfarekinom a dose of 5 million IU daily performed within 10-12 months.
Volosatokletochnaya leukemia: from 3 million IU 3 times a week / m (a day) for 4-6 weeks. When the phase of remission maintenance therapy is carried out: by 3 million IU a day - up to 12 months.
Non-Hodgkin's lymphoma: by 3 million IU 3 times a week / m over 12-18 months as maintenance therapy in achieving remission phase reached as a result of chemotherapy.
CONTRAINDICATIONS: Hypersensitivity to interferon alfa-2b or to other components of the drug during pregnancy (threatened miscarriage).
SIDE EFFECTS: Injecting Alfarekina in most cases accompanied by flu-like syndrome: fever, chills, headache and muscle pain, joint pain, general weakness. These side effects are dose-dependent, and usually occur only in the first days of treatment, then decrease and disappear. To treat or a significant reduction of symptoms used paracetamol 0,5-1 g for 30-40 min before injection.
Sometimes when long courses of treatment indicated leukopenia, thrombocytopenia, passing with a decrease in dose.
STORAGE: at 2-8 ° S.
Prepared pp preparation for injection used immediately; rr for intranasal administration can be stored for 1 day at 2-8 ° C (refrigerated).
The mechanism of action Alfarekina based on the binding of IFN to specific receptors of cells of the body, resulting in triggered cascade of intracellular reactions, and synthesis of enzymes which depress viral replication, increased phagocytic activity of macrophages and lymphocytes specific cytotoxicity on target cells, inhibiting proliferation of metastatic cells.
INDICATIONS: in the complex therapy of children and adults with:
Viral hepatitis B and C;
acute viral, bacterial and mixed infections (including neonatal);
acute and chronic purulent diseases of viral and bacterial origin;
herpetic infections of different localization: (tinea, multiple cutaneous herpetic eruptions, genital herpes infection, herpetic keratoconjunctivitis and keratouveit, etc.);
chronic urogenital chlamydiosis;
lesions of the nervous system with mono-and poliradikulyarnym pain syndrome;
laryngeal papillomatosis;
multiple sclerosis;
malignancies: melanoma of skin and eye cancer, kidney, bladder, ovaries, breast cancer, Kaposi's sarcoma, myeloma;
hemoblastosis: chronic myeloid leukemia, volosatokletochnoy leukemia, non-Hodgkin's lymphoma.
APPLICATION: rr Alfarekina injected i / m, n / k / v, endolimfalno, intraperitoneal, intravesical, rectal, parabulbarno, intranasal. The dissolution of the contents of the vial in 1 ml of water as a solvent used for injection by dissolving the contents of the vial at a higher level using physiological pp.
Acute hepatitis B:
introduced on 1 million IU (in severe cases - by 2 million IU) in / m 2 twice daily for 10 days. The course of treatment may be extended to 2-3 weeks, depending on the patient's general condition, or extended by 1 million IU 2 times a week for several weeks.
Chronic viral hepatitis B:
injected i / m for 3-4 million IU 3 times a week for 2 months.
Chronic viral hepatitis C:
introduced into / m 3 million IU 3 times a week for 6 months as monotherapy or in combination with drugs-nucleoside analogues.
SARS in children (including newborns):
injected intranasally with 2-3 drops into each nasal passage 3-6 times a day for 3-5 days; dosage for newborns - 20-50 thousand IU / ml, for children of other age groups - 100 thousand IU / ml.
Acceptable introduction to the nasal passages (alternately) padded turundae wetted Alfarekinom, 10-15 min.
ARI (including influenza) in adults:
injected i / m by 1-3 million IU, beginning with 1-2 days of disease within 3 days;
intranasal imposed on 4-6 drops of p-ra Alfarekina (100 thousand IU / ml) in each nasal passage 6-8 times a day (to be entered using a dose Alfarekina should be heated in the syringe (use a syringe without the needle) to body temperature, the rest rr stored in the refrigerator, protected from bacterial contamination).
Acute and recurrent viral pneumonia and viral-bacterial etiology:
V / m at 1 million IU for 5-7 days in the complex treatment, including antibacterial, detoxication, anti-inflammatory therapy.
Acute diarrheal syndrome in infants:
rectally in the form of daily mikroklizmochek containing 100 thousand IU Alfarekina within 3-7 days.
Acute intestinal infections in young children with symptoms hypocoagulation:
injected rectally in a dose of 10 thousand IU / kg body weight 3 times with an interval of 48 h.
Purulent-septic disease, peritonitis, multiple abscesses of the abdominal cavity:
in / on 2-4 million IU 1 time per day, total dose: 12-16 million IU per course of treatment.
HSV infection:
zoster: daily / m - 1 million IU, and 2 million IU in 5 ml of physiological p-ra n / a at several points around the zone of the rash. Duration of treatment - 5-7 days.
cutaneous herpetic eruptions: 2 million IU / m or s / c (around lesion) daily; treatment can be combined with local application (applications) on herpetic papules.
Genital herpes infection: 2 million IU / m daily in combination with local application of the drug in the form of applications to the region of eruption.
herpetic keratoconjunctivitis: 1 million IU Alfarekina dissolved in 5 ml of physiological p-ra, injected conjunctiva with 2-3 drops every 2 h for 7-10 days, with decreasing severity of symptoms of a drug can enter every 4 hours
Chronic urogenital chlamydia:
Alfarekin used in complex therapy - to 1 million IU / m 1 times a day in the evening, on a course of treatment - 10 injections.
The defeat of the nervous system with mono-and poliradikulyarnym pain syndrome:
of 1 million IU / m for 5-10 days in the complex therapy.
Laryngeal papillomatosis:
in / m (if possible - in the perifocal area of the larynx) introduction Alfarekina a dose of 100-150 thousand IU / kg of body weight daily for 20-25 days. It is recommended to repeat this course of treatment with an interval of 1-1,5 months within 6 months, followed at intervals of 2-3 months for the next 6 months.
Multiple sclerosis:
V / m at 1 million IU 2-3 times a day for 10-15 days, then - by 1 million IU 1 times per week for 6 months.
Malignancies
Melanoma of the skin - by 3 million IU / m 1 times a day - 10 days with an interval of 1.5 months of repeating this course for 6 months;
or: by 3 million IU Alfarekina 4 times with an interval of 48 hours - endolimfalno followed lymphotropic drug administration for 1 million IU for 4 days every month.
Uveal melanoma: the 1 million IU parabulbarno daily for 10 days, 20 days later to repeat the course within 10 days, 2 times; dose of the drug on the general course of treatment is 30 million IU. Can not exclude the need for repeated courses in 45 days; treatment Alfarekinom combined with photodestruction of the tumor and beta applications.
Kidney cancer: by 3 million IU / m, daily for 10 days, the overall rate - 30 million IU, refresher courses held at intervals of 3-5 weeks for 6 months, and then at intervals of 1,5-2 months in within 1 year.
Bladder cancer: intravesical instillation in the form of, for 5-10 million IU per instillation, 3-6 times. The total course dose - 30 million IUs. The treatment is repeated every 2-3 months for 1 year-2 years.
Cancer of the ovary: 5 million IU injected intraperitoneally during surgery and in the next 5 days - in the drainage, then - at 3 million IU / m for 10 days between courses of chemotherapy, the total course dose Alfarekina of 90 million IU. Subsequent courses may be assigned at intervals of 2-3 months for 1-1,5 years: by 3 million IU / m every day - 10 days.
Breast Cancer: by 3 million IU per injection in / m, daily for 10 days. Repeated courses are held at intervals 1,5-2 months to 1 year and then every 2-3 months (depending on the clinical condition of the patient), appropriate alternate therapy Alfarekinom with courses of chemotherapy (or radiotherapy).
Kaposi's sarcoma: by 3 million IU per injection in / m, daily for 10 days; treatment combined with monohimioterapiey prospidin; repeated courses - 1 time per month for 6 months.
Multiple myeloma: by 3 million IU per injection in / m, daily for 10 days, a second course - 1 times 1,5-3 months (4-6 courses during the year).
Hemoblastosis
Chronic myeloid leukemia: 5 million IU / m daily.
Apply as in the form of mono-and chemotherapy in the complex. Duration of treatment - 6 months. When the phase of remission maintenance therapy Alfarekinom a dose of 5 million IU daily performed within 10-12 months.
Volosatokletochnaya leukemia: from 3 million IU 3 times a week / m (a day) for 4-6 weeks. When the phase of remission maintenance therapy is carried out: by 3 million IU a day - up to 12 months.
Non-Hodgkin's lymphoma: by 3 million IU 3 times a week / m over 12-18 months as maintenance therapy in achieving remission phase reached as a result of chemotherapy.
CONTRAINDICATIONS: Hypersensitivity to interferon alfa-2b or to other components of the drug during pregnancy (threatened miscarriage).
SIDE EFFECTS: Injecting Alfarekina in most cases accompanied by flu-like syndrome: fever, chills, headache and muscle pain, joint pain, general weakness. These side effects are dose-dependent, and usually occur only in the first days of treatment, then decrease and disappear. To treat or a significant reduction of symptoms used paracetamol 0,5-1 g for 30-40 min before injection.
Sometimes when long courses of treatment indicated leukopenia, thrombocytopenia, passing with a decrease in dose.
STORAGE: at 2-8 ° S.
Prepared pp preparation for injection used immediately; rr for intranasal administration can be stored for 1 day at 2-8 ° C (refrigerated).
No comments:
Post a Comment